New Horizons in the Treatment and Management of Ovarian Cancer: What Managed Care Needs to Know About Recent Advances in PARP Inhibitors

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management of ovarian cancer

These are archives of live webinars held between June 15 to June 19, 2020.

If you participated in any of the live webinars, you are not eligible
to claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all three or in order.

These activities are valid from July 1, 2020 to July 1, 2022

Each session has its own specific valid dates

This activity is supported by educational grants from
AstraZeneca, GlaxoSmithKline, and Merck Sharp & Dohme Corp.

 

 Audience: This activity is intended for healthcare professionals practicing in managed care environments.

 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
There will be an estimated 22,440 new cases of ovarian cancer this year in the United States, and an estimated 14,080 deaths. Ovarian cancer is usually found late, stage 3 or higher, where it has already spread or metastasized to other parts of the abdomen, or worse. The five year survival rate is only 45%. Fortunately for patients with ovarian cancer, the treatment paradigm has exploded in the past three years, giving HCPs more options in managing patients with ovarian cancer. Leading the way in new options for ovarian cancer are PARP inhibitors, which have shown improved efficacy for patients with ovarian cancer.


Comparative Effectiveness and Coordinated Care in Ovarian Cancer: What Does Managed Care Need to Know About PARP Inhibitors?

  1. Outline the economic burden of ovarian cancer and the goals of remission maintenance that can be addressed by clinical pathways
  2. Compare and contrast the safety and efficacy profiles of PARP inhibitors in cancer therapy in ovarian cancer
  3. Assess the managed care considerations of PARP inhibitors by exploring where these agents fit into the current ovarian cancer management paradigm
  4. Discuss the role of managed care professionals within the collaborative care team for effective therapy management for patients with ovarian cancer
          Physician, Nursing and CMCN credits valid to July 1, 2022

A Deeper Look into PARP Inhibitors in the Management of Ovarian Cancer: Individualizing Treatment for Improved Clinical and Economic Outcomes

  1. Assess the role of the DNA damage response (DDR) pathway in tumor suppression and describe how mutations in DDR genes lead to tumor proliferation
  2. Outline the clinical burden of ovarian cancer and the goals of remission maintenance that can be addressed by clinical pathways
  3. Analyze safety and efficacy outcomes from recent clinical data on PARP inhibitors, both in the maintenance setting and in the setting of recurrence following prior use of platinum-based therapy
  4. Explore the role of PARP inhibitors as a first-line maintenance therapy for patients with ovarian cancer
  5. Examine genetic testing and biomarkers for the identification of patients with ovarian cancer to be treated with PARP inhibition, including those with BRCA-mutated disease
          Physician, Nursing and CMCN credits valid to July 1, 2022

Improving Patient Adherence and Quality of Life in Ovarian Cancer: Strategies for Anticipating, Recognizing, and Managing Adverse Events Associated with PARP Inhibitors

  1. Compare PARP inhibitors in ovarian cancer therapy including mechanisms of action, delivery methods, dosing and scheduling, efficacy, safety, interactions, and ease of use
  2. Define strategies for anticipating, recognizing, and managing adverse events of PARP inhibitor therapy in patients with ovarian cancer
  3. Analyze safety outcomes from recent clinical data on PARP inhibitors in ovarian cancer, both in the maintenance setting and in the setting of recurrence following prior use of platinum-based therapy
  4. Discuss methods to communicate effectively with ovarian cancer patients and the multidisciplinary team to understand and address the needs of each patient around PARP inhibitors and improve treatment adherence, quality of life, and survival outcomes
          Physician, Nursing and CMCN credits valid to July 1, 2022